[Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy].
In a 59-year-old male with a 10 year history of Parkinson's disease, progressive movement disorders occurred under medical treatment (end-of-dose akinesia and peak-dose dyskinesia). Thereupon his treatment was changed to a combination of L-dopa/ decarboxylase inhibitor administered during the day in 5 fractions, and additionally a slow-release dopa preparation given on retiring for the night. At the same time, the patient received the dopamine agonist lisuride. While the patient was hospitalized for surgery, his anti-parkinsonism regimen was initially stopped and then continued in changed form. In the following weeks he experienced a drastic impairment of mobility and, in particular, suffered pronounced nocturnal hypokinetic events. A second period of hospitalization became necessary, a complex medical therapeutic regimen similar to the previously successful combination was established. This resulted in satisfactory mobility, and the patient was able to go back to work.
Fuchs
G
G
Parkinson-Klinik Wolfach.
D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000009:adverse effects; D018491:Dopamine Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage* / Q000009:adverse effects; D008090:Lisuride / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy / Q000209:etiology
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007980:Levodopa; D008090:Lisuride
Morbus Parkinson--Probleme der Langzeitbehandlung. Dopaminagonisten optimieren die L-Dopa-Therapie.